U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H41F2N5O
Molecular Weight 513.6655
Optical Activity ( - )
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Maraviroc

SMILES

CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5

InChI

InChIKey=GSNHKUDZZFZSJB-QYOOZWMWSA-N
InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25-,26-/m0/s1

HIDE SMILES / InChI
Molecular Formula C29H41F2N5O
Molecular Weight 513.6655
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16251317

Maraviroc (UK-427,857; brand-named Selzentry, or Celsentri outside the U.S) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. Maraviroc is the product of a medicinal chemistry effort initiated following identification of an imidazopyridine CCR5 ligand from a high-throughput screen of the Pfizer compound file. Selzentry, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled trials of SELZENTRY in treatment-experienced subjects and one trial in treatment-naive subjects. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the cell membrane, preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. CXCR4-tropic and dual-tropic HIV-1 entry is not inhibited by maraviroc. Antiviral Activity in Cell Culture Maraviroc inhibits the replication of CCR5-tropic laboratory strains and primary isolates of HIV-1 in models of acute peripheral blood leukocyte infection. The mean EC50 value (50% effective concentration) for maraviroc against HIV-1 group M isolates (subtypes A to J and circulating recombinant form AE) and group O isolates ranged from 0.1 to 4.5 nM (0.05 to 2.3 ng per mL) in cell culture. When used with other antiretroviral agents in cell culture, the combination of maraviroc was not antagonistic with NNRTIs (delavirdine, efavirenz, and nevirapine), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), or protease inhibitors (amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir). Maraviroc was not antagonistic with the HIV fusion inhibitor enfuvirtide. Maraviroc was not active against CXCR4-tropic and dual-tropic viruses (EC50 value greater than 10 µM). The antiviral activity of maraviroc against HIV-2 has not been evaluated. Maraviroc can cause serious, life-threatening side effects such as, liver problems, skin reactions, and allergic reactions.

CNS Activity

CNS Active
4002
Curator's Comment: Several factors suggest maraviroc may have CNS antiviral activity. First, due to pharmacological properties, such as a relatively low degree of plasma protein binding (∼76%), maraviroc may theoretically cross the blood–brain barrier (BBB) and gain exposure in the CSF at concentrations great enough to suppress HIV viral replication. Second, as a predominance of CCR5-tropic HIV has been described within the CNS, CCR5 inhibitors such as maraviroc may have profound antiviral activity within this compartment.

Originator

Pfizer
420
Curator's Comment: from a high-throughput screen of the Pfizer compound file # Pfizer

Approval Year

2007
239
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 0.86 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
SELZENTRY

Approved Use

SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of SELZENTRY in treatment-experienced subjects and one study in treatment-naïve subjects. Both studies in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviral-experienced (NRTI, NNRTI, PI, or enfuvirtide) adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY. Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for SELZENTRY use. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY. [see Microbiology (12.4) Clinical Studies (14.3)

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
335.6 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: healthy
age:
sex:
food status:
801.16 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
888 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022128s018,208984s001lbl.pdf
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MARAVIROC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
538 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/18333861
300 mg 2 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MARAVIROC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1320.7 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1348.4 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: healthy
age:
sex:
food status:
4255.5 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
4367.7 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
2908 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022128s018,208984s001lbl.pdf
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MARAVIROC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
2422 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/18333861
300 mg 2 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MARAVIROC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.36 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: healthy
age:
sex:
food status:
17.29 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00717067
300 mg single, oral
dose: 300 mg
route of administration: oral
experiment type: single
co-administered:
MARAVIROC plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
8.63 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/18333861
300 mg 2 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MARAVIROC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63608
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63608
eMolecules
32275895
https://www.emolecules.com/cgi-bin/more?vid=32275895
MolPort
MolPort-020-005-896
https://www.molport.com/shop/molecule-link/MolPort-020-005-896
ZINC
ZINC000100003902
http://zinc15.docking.org/substances/ZINC000100003902
PubMed

PubMed

TitleDatePubMed
CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.
2008-06-01
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
2008-04
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
2008-04
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
2008-04
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
2008-04
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
2008-04
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
2008-04
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
2008-04
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
2008-04
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
2008-04
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
2008-04
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
2008-04
A review of the clinical pharmacology of maraviroc. Introduction.
2008-04
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
2008-03
Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
2008-02-15
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.
2008-02-01
Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
2008-01-18
Two new drugs for HIV infection.
2008-01-14
Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person.
2008-01
Asymmetric allylboration of acyl imines catalyzed by chiral diols.
2007-12-12
Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
2007-12-05
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
2007-12
Allosteric modulation of heterodimeric G-protein-coupled receptors.
2007-12
Anti-HIV agents. New drugs--hope and a degree of caution.
2007-11-29
Anti-HIV agents. Using maraviroc in first-line therapy.
2007-11-29
Anti-HIV agents. Maraviroc and resistance.
2007-11-29
Anti-HIV agents. One year clinical trial results with maraviroc.
2007-11-29
Anti-HIV agents. Maraviroc approved in Canada.
2007-11-29
New drugs: Maraviroc and Lanreotide.
2007-11-23
Randomized trials to optimize treatment of multidrug-resistant tuberculosis.
2007-11-06
Maraviroc.
2007-11
Antiviral drugs in the treatment of AIDS: what is in the pipeline ?
2007-10-15
Treatment with CCR5 antagonists: which patient may have a benefit?
2007-10-15
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
2007-10-15
CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
2007-10-15
CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
2007-10-15
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
2007-10-15
Changes in HIV-1 tropism: clinical and prognostic consequences.
2007-10-15
Maraviroc approved in the European Union.
2007-10
Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.
2007-09-26
Novel HIV treatment approved.
2007-09-15
Maraviroc reduces viral load in naive patients at 48 weeks.
2007-09
FDA approves maraviroc tablets.
2007-09
FDA approves drug for resistant HIV.
2007-09
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
2007-08-24
Maraviroc--new HIV drug. Emerging options need to be used wisely.
2007-08-09
First medication in new class of ARTs poised to be available for salvage therapy. Tropism testing helps determine best patients for drug.
2007-08
Report from the XVI International HIV Drug Resistance Workshop.
2007-08
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
2007-08
Maraviroc.
2007
Patents

Patents

08779143
2
20050282907
3
JP2011508747A
62
JP2011508748A
30

Sample Use Guides

In Vivo Use Guide
The recommended dose of SELZENTRY (maraviroc tablets, for oral use) differs based on concomitant medications due to drug interactions. SELZENTRY can be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications.
Route of Administration: Oral
In Vitro Use Guide
PM-1 cells were infected with CCR5-tropic HIV-1 BaL in the presence or absence of inhibitory concentrations of maraviroc (MVC) 50 nM or controls. P24 and viral load levels were measured by ELISA and qRT-PCR after 4 hours.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:03:21 GMT 2025
Edited
by admin
on Mon Mar 31 18:03:21 GMT 2025
Record UNII
MD6P741W8A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide
Preferred Name English
Maraviroc
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
maraviroc [INN]
Common Name English
MARAVIROC [EMA EPAR]
Common Name English
MARAVIROC [VANDF]
Common Name English
MARAVIROC [MART.]
Common Name English
MARAVIROC [JAN]
Common Name English
Maraviroc [WHO-DD]
Common Name English
Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-
Systematic Name English
CELSENTRI
Brand Name English
UK-427,857
Code English
SELZENTRY
Brand Name English
MARAVIROC [MI]
Common Name English
MARAVIROC [ORANGE BOOK]
Common Name English
UK-427857
Code English
Classification Tree Code System Code
LIVERTOX NBK548266
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
NDF-RT N0000175572
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
WHO-VATC QJ05AX09
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
NCI_THESAURUS C1660
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
NCI_THESAURUS C63817
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
EMA ASSESSMENT REPORTS CELSENTRI (AUTHORIZED: HIV INFECTIONS)
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
WHO-ATC J05AX09
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
NDF-RT N0000175445
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
Code System Code Type Description
MESH
C502411
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
HSDB
8021
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID8048949
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
DRUG CENTRAL
1635
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
IUPHAR
806
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
INN
8450
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
EVMPD
SUB25224
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
DAILYMED
MD6P741W8A
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
CAS
376348-65-1
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
NCI_THESAURUS
C73144
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
FDA UNII
MD6P741W8A
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
MERCK INDEX
m7084
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL1201187
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
SMS_ID
100000089254
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
RXCUI
620216
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
MARAVIROC
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
CHEBI
63608
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
LACTMED
Maraviroc
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
DRUG BANK
DB04835
Created by admin on Mon Mar 31 18:03:21 GMT 2025 , Edited by admin on Mon Mar 31 18:03:21 GMT 2025
PRIMARY
Related Record Type Details
Structure of Maraviroc
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
C-C CHEMOKINE RECEPTOR TYPE 5
TARGET -> INHIBITOR
Blocks HIV infection
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of Maraviroc
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
Related Record Type Details
Structure of (5-ISOPROPYL-4-((1R,5S)-8-METHYL-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-1,2,4-TRIAZOL-3-YL)METHANOL
METABOLITE -> PARENT
Structure of 4,4-DIFLUORO-N-((1S)-3-((1R,5S)-3-(3-(HYDROXYMETHYL)-5-ISOPROPYL-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO(3.2.1)OCTAN-8-YL)-1-PHENYL-PROPYL)CYCLOHEXANECARBOXAMIDE
METABOLITE -> PARENT
Structure of (1S,2S)-2-HYDROXYMARAVIROC
METABOLITE -> PARENT
Structure of UK-437719
METABOLITE -> PARENT
<1% radioactivity
MINOR
FECAL; PLASMA; URINE
Structure of (1S,3S)-3-HYDROXYMARAVIROC
METABOLITE -> PARENT
Structure of (1R,2R)-2-HYDROXYMARAVIROC
METABOLITE -> PARENT
Structure of (1S,3R)-3-HYDROXYMARAVIROC
METABOLITE -> PARENT
Related Record Type Details
Structure of (S)-3-(4,4-DIFLUOROCYCLOHEXANE-1-CARBOXAMIDO)-3-PHENYLPROPANOIC ACID
IMPURITY -> PARENT
Structure of (?S,3-exo)-3-[3-Methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-?-phenyl-8-azabicyclo[3.2.1]octane-8-propanamine
IMPURITY -> PARENT
Structure of TEMPO
IMPURITY -> PARENT
Structure of 4,4-Difluoro-N-[(1S)-3-oxo-1-phenylpropyl]cyclohexanecarboxamide
IMPURITY -> PARENT
Related Record Type Details
Structure of Maraviroc
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE AND MULTIPLE DOSE

blood-to-plasma ratio PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966